{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Paliperidone", "query": { "intervention": "Paliperidone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Paliperidone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T12:15:19.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02462473", "title": "A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 9, "start_date": "2015-05", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 3, "location_summary": "Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Conshohocken", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02462473" }, { "nct_id": "NCT01411085", "title": "Risperidone and Desipramine in Alcohol Use and Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia", "Alcoholism", "Dual Diagnosis" ], "interventions": [ { "name": "Risperidone + Desipramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 4, "location_summary": "Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01411085" }, { "nct_id": "NCT02087579", "title": "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psychotic Disorders", "Schizophrenia", "Bipolar Disorder", "Depressive Disorder" ], "interventions": [ { "name": "Aripiprazole, oral formulation", "type": "DRUG" }, { "name": "Olanzapine, oral formulation", "type": "DRUG" }, { "name": "Paliperidone, oral formulation", "type": "DRUG" }, { "name": "Paliperidone, LAI", "type": "DRUG" }, { "name": "Quetiapine, oral formulation", "type": "DRUG" }, { "name": "Risperidone, oral formulation", "type": "DRUG" }, { "name": "Risperidone, LAI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 305, "start_date": "2014-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-10-29", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 6, "location_summary": "Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hoffman Estates", "state": "Illinois" }, { "city": "Cedarhurst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087579" }, { "nct_id": "NCT03557931", "title": "A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "brexpiprazole", "type": "DRUG" }, { "name": "paliperidone", "type": "DRUG" }, { "name": "lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 233, "start_date": "2018-07-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 27, "location_summary": "Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557931" }, { "nct_id": "NCT02600741", "title": "Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Caregiver psycho-education and skills training", "type": "OTHER" }, { "name": "Caregiver support available at the study site", "type": "OTHER" }, { "name": "Paliperidone palmitate", "type": "DRUG" }, { "name": "Chlorpromazine", "type": "DRUG" }, { "name": "Droperidol", "type": "DRUG" }, { "name": "Fluphenazine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Loxapine", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Pimozide", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "DRUG" }, { "name": "Thiothixene", "type": "DRUG" }, { "name": "Thioridazine", "type": "DRUG" }, { "name": "Trifluoperazine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Iloperidone", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 296, "start_date": "2015-07-24", "completion_date": "2018-07-05", "has_results": false, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 34, "location_summary": "Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Lauderdale Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600741" }, { "nct_id": "NCT01559272", "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Paliperidone IR (Period 1)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel A: treatment group 1)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel A: treatment group 2)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel B: treatment group 1)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel B: treatment group 2)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel B: treatment group 3)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel B: treatment group 4)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel B: treatment group 5)", "type": "DRUG" }, { "name": "Paliperidone palmitate F016", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel D: treatment group 1)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel D: treatment group 2)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel D: treatment group 3)", "type": "DRUG" }, { "name": "Paliperidone palmitate F015 (Panel D: treatment group 4)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 328, "start_date": "2008-02-21", "completion_date": "2014-05-24", "has_results": false, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01559272" }, { "nct_id": "NCT00589914", "title": "Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "RISPERDAL CONSTA", "type": "DRUG" }, { "name": "Paliperidone palmitate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1221, "start_date": "2007-03", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-06-24", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589914" }, { "nct_id": "NCT02893371", "title": "Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Fluoxetine / Olanzapine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Lurasidone", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Mirtazapine", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Desvenlafaxine", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" }, { "name": "Doxepin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1037352, "start_date": "2016-09", "completion_date": "2019-06-30", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893371" }, { "nct_id": "NCT00946985", "title": "28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "paliperidone palmitate", "type": "DRUG" }, { "name": "oral risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ortho-McNeil Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 163, "start_date": "2009-06", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946985" }, { "nct_id": "NCT00111189", "title": "A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Paliperidone Palmitate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 414, "start_date": "2005-02", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-09-02T12:15:19.737Z", "location_count": 18, "location_summary": "Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111189" } ] }